Mace L. Rothenberg
Vanderbilt University(US)Nashville Oncology Associates(US)International Drug Development(FR)Ribon Therapeutics (United States)(US)Vanderbilt University Medical Center(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics
Most-Cited Works
- → Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.(1997)5,865 cited
- → Matrix Metalloproteinases: Biologic Activity and Clinical Implications(2000)1,548 cited
- → Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial(2003)643 cited
- → Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial(2002)578 cited
- → A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer(1996)569 cited
- → Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer